This website has been developed by Besins Healthcare (UK) Ltd.

This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) 16.2 mg/g gel, within the UK.

Please confirm that:

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Starting the conversation with your patients…

Starting the conversation with your patients

Practical advice

Setting up Testogel® 16.2 mg/g gel1

Before first use, patients need to prepare the gel pump to ensure delivery of a consistent dose.

Step 1

Step 1

Remove the cap from the canister to reveal the plunger

Step 2

Step 2

Press the plunger down three times, collecting the gel on a tissue

Step 3

Step 3

Do not use the gel released and safely discard it in a rubbish bin

The pump is now ready to use and these steps do not have to be performed again.

Applying Testogel® 16.2 mg/g gel1


Assure patients that application is straight forward and that they are aware of the following steps:

  • Apply the gel at the same time every day, onto clean, dry, healthy skin. Apply as a thin layer on both shoulders and upper arms (no need to rub in)
  • Leave to dry – Testogel® 16.2 mg/g gel dries within 3–5 minutes
  • DO NOT apply to the upper chest, genitals or abdomen

Wash your hands

  • With soap and water, after applying gel
  • Wait at least 2 hours after gel application before washing or bathing

Cover up

  • After it dries, the area should be covered with clothing
  • If someone else comes into contact with the application site, they should wash their skin with soap and water as soon as possible

Wash application areas before any direct skin contact with someone else.

Testogel® is flammable until dry.

Watch this video to find out more on how to apply Testogel® 16.2 mg/g gel and how it works:

How to apply Testogel® 16.2 mg/g gel

How to prepare your pump dispenser containing Testogel® 16.2
mg/g gel for the first time and for daily application.



Transfer risk

Transfer risk

Testosterone can be transferred to others through direct skin-on-skin contact. In order to prevent this, equip your patients with the following information:

How to avoid transfer risk:1

  • Wash their hands with soap and water after applying the gel
  • Cover the application area with clothing once the gel has dried
  • It may be best for patients to apply the gel in the morning before dressing for the day
  • Take a shower before any anticipated skin-to-skin contact

If a patient thinks they have transferred testosterone:1

  • Wash the area that may have been affected immediately with soap and water
  • Report any signs of testosterone exposure to the doctor. Acne, or changes in the growth or pattern of hair are all signs of potential exposure to testosterone
Missing a dose/application

Missing a dose/application

If a patient misses a dose or removes the gel by accident, they do not need to reapply or take a ‘double’ dose. The gel should be applied at the usual time the following day.

For more information for patients, download the Testogel® 16.2 mg/g gel package leaflet, which is also contained within their medication.

Duration of treatment

Duration of Treatment

Watch Professor Abraham Morgentaler of the Harvard Medical
School in Boston discuss the Duration of Testosterone Therapy.

Professor Abraham Morgentaler

It is important to manage your patient’s expectations and advise them that some of their symptoms will take longer than others to improve. This will help to ensure patients continue with the treatment even if results are not immediately seen.

Many of the symptoms of testosterone deficiency (TD) will start to improve within 3 months. However, the maximum effect of treatment on most symptoms is seen at 6–12 months.2

Find more information on specific symptom relief timelines.


Assess response to therapy at 2–4 weeks, 3–6 months, 12 months, and then annually thereafter.3,4

Aim for a target testosterone level of 15–30 nmol/L to achieve optimal response.3

Monitor haematocrit before treatment, at 3–6 months, 12 months, and annually thereafter. Decrease dosage or switch preparation if haematocrit is >0.54; if haematocrit remains high, consider stopping treatment and reintroduce at a lower dose.3

Assess prostate health by prostate-specific antigen test (PSA) and digital rectal exam (DRE) before commencing testosterone therapy (TTh) followed by PSA at 3–6 months, 12 months, and then every 12 months following.3

Assess cardiovascular risk before TTh is initiated and monitor cardiovascular risk throughout therapy.3

In addition to the general TTh monitoring described above, the Testogel® 16.2 mg/g gel Summary of Product Characteristics (SPC) also recommends that the following be monitored regularly: haemoglobin, liver function tests, and lipid profile. Please refer to the SPC for further information.

Transitioning patients from Testogel® 50 mg Sachet to Testogel® 16.2 mg/g gel

The recommended starting dose for Testogel® 50 mg Sachet is one sachet, for Testogel® 16.2 mg/g gel it is two actuations of the pump.5

There are no comparative dosing studies that advise on how patients can be switched from one formulation of Testogel® to the other. The guidance in the individual products’ SPC should be followed when starting and titrating the dose of a particular Testogel® formulation.1,5


  1. Testogel® 16.2 mg/g gel – Summary of Product Characteristics (SmPC) – Accessed April 2021.
  2. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–685.
  3. Hackett G, Kirby M, Edwards D, et al. British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice. J Sex Med. 2017;14(12):1504–1523.
  4. Ullah MI, Riche DM, Koch CA. Transdermal testosterone replacement therapy in men. Drug Des Devel Ther. 2014;8:1010–112.
  5. Testogel® 50mg gel in sachet – Summary of Product Characteristics (SmPC) – Accessed April 2021.

TES/2020/009. April 2021.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: